Tigermed to snag top-end price for $1.4bn Hong Kong IPO
GlobalCapital, is part of the Delinian Group, DELINIAN (GLOBALCAPITAL) LIMITED, 4 Bouverie Street, London, EC4Y 8AX, Registered in England & Wales, Company number 15236213
Copyright © DELINIAN (GLOBALCAPITAL) LIMITED and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement
Cookies Settings
Asia

Tigermed to snag top-end price for $1.4bn Hong Kong IPO

Jonathan Breen
July 31, 2020 08:00 AM
biopharma_stocks_adobe_575x375.jpg

Hangzhou Tigermed Consulting is set to pocket HK$10.7bn ($1.38bn) from its Hong Kong secondary listing, with solid support from Chinese and global investors driving final pricing to the top of guidance.

Unlock this article.

The content you are trying to view is exclusive to our subscribers.

To unlock this article:

Request a Free Trial or Login

Topics

CITIC SecuritiesCredit SuisseUBSEquityChina Merchants Bank CoChinaBank of AmericaChina International Capital CorpJefferies LLCHong Kong SARICBCAsiaCoronavirusGreater ChinaHaitong SecuritiesNortheast AsiaAsia PacificEmerging Markets
JB
Jonathan Breen
Equities editor GlobalCapital Asia
Contact
Gift this article